Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts

C Anderberg, H Li, L Fredriksson, J Andrae… - Cancer research, 2009 - AACR
C Anderberg, H Li, L Fredriksson, J Andrae, C Betsholtz, X Li, U Eriksson, K Pietras
Cancer research, 2009AACR
Cancer results from the concerted performance of malignant cells and stromal cells. Cell
types populating the microenvironment are enlisted by the tumor to secrete a host of growth-
promoting cues, thus upholding tumor initiation and progression. Platelet-derived growth
factors (PDGF) support the formation of a prominent tumor stromal compartment by as of yet
unidentified molecular effectors. Whereas PDGF-CC induces fibroblast reactivity and fibrosis
in a range of tissues, little is known about the function of PDGF-CC in shaping the tumor …
Abstract
Cancer results from the concerted performance of malignant cells and stromal cells. Cell types populating the microenvironment are enlisted by the tumor to secrete a host of growth-promoting cues, thus upholding tumor initiation and progression. Platelet-derived growth factors (PDGF) support the formation of a prominent tumor stromal compartment by as of yet unidentified molecular effectors. Whereas PDGF-CC induces fibroblast reactivity and fibrosis in a range of tissues, little is known about the function of PDGF-CC in shaping the tumor-stroma interplay. Herein, we present evidence for a paracrine signaling network involving PDGF-CC and PDGF receptor-α in malignant melanoma. Expression of PDGFC in a mouse model accelerated tumor growth through recruitment and activation of different subsets of cancer-associated fibroblasts. In seeking the molecular identity of the supporting factors provided by cancer-associated fibroblasts, we made use of antibody arrays and an in vivo coinjection model to identify osteopontin as the effector of the augmented tumor growth induced by PDGF-CC. In conclusion, we establish paracrine signaling by PDGF-CC as a potential drug target to reduce stromal support in malignant melanoma. [Cancer Res 2009;69(1):369–78]
AACR